GO:2001024 negative regulation of response to drug: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001024 (negative regulation of response to drug) is a biological process that reduces or prevents the cellular, physiological, or behavioral effects of a drug.
• It is distinct from drug resistance: it describes regulatory mechanisms that actively suppress drug responses, not merely the absence of a drug target.
• Key molecular players include drug-metabolizing enzymes (CYP3A4, CYP2D6), transporters (ABCB1, ABCG2), nuclear receptors (NR1I2, NR1I3), and epigenetic regulators (KDM5A, HDACs).
• Dysregulation of this process contributes to therapeutic failure in cancer, infectious disease, and neurological disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting causal genes in this pathway.
• High-throughput CRISPR library screening combined with bioinformatics can identify novel negative regulators of drug response.
Description
Negative regulation of response to drug (GO:2001024) is a biological process that actively reduces, prevents, or reverses the cellular and physiological effects of a pharmacological agent. This term captures regulatory mechanisms that suppress drug sensitivity, including transcriptional repression of drug targets, induction of drug efflux pumps, activation of survival signaling, and epigenetic silencing of pro-apoptotic genes. Understanding this process is critical because it underlies therapeutic resistance, variable drug efficacy, and adverse drug reactions across multiple disease areas. In cancer, for example, negative regulation of response to drug can mediate resistance to targeted therapies and chemotherapies, leading to treatment failure and poor patient outcomes. In infectious disease, similar mechanisms can reduce antibiotic or antiviral efficacy. Researchers studying GO:2001024 aim to identify the genes, pathways, and environmental factors that suppress drug responses, with the goal of developing strategies to overcome resistance or to intentionally dampen unwanted drug effects. This article integrates authoritative QuickGO annotation data with real PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease relevance, and experimental models for studying negative regulation of response to drug.
negative regulation of response to drug At A Glance
| GO ID | GO:2001024 |
|---|---|
| GO term | negative regulation of response to drug |
| Ontology | biological_process |
| Synonym | None |
| Major function | Actively reduces or prevents the cellular, physiological, or behavioral effects of a drug |
| Related processes | Drug metabolism, drug transport, signal transduction, epigenetic regulation |
| Key regulators | CYP3A4, CYP2D6, ABCB1, ABCG2, NR1I2, NR1I3, KDM5A, HDACs |
| Disease relevance | Cancer therapy resistance, antibiotic resistance, antiviral failure, adverse drug reactions |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, high-throughput screening |
What Is GO:2001024?
Negative regulation of response to drug (GO:2001024) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of a response to a drug. In other words, it encompasses biological mechanisms that actively suppress the cellular, physiological, or behavioral effects of a pharmacological substance. This regulation can occur at multiple levels, including drug metabolism, transport, target engagement, signal transduction, and gene expression. It is a biological_process term in the Gene Ontology, and it is distinct from drug resistance, which often involves genetic mutations or target alterations; negative regulation emphasizes active regulatory pathways that modulate drug response.
Why Is negative regulation of response to drug Important in Cell Biology?
Negative regulation of response to drug is critically important because it directly impacts therapeutic efficacy and patient safety. In oncology, active suppression of drug response can lead to resistance to chemotherapy, targeted inhibitors, and immunotherapies, resulting in disease progression and mortality. In infectious diseases, similar mechanisms can reduce the effectiveness of antibiotics and antivirals, contributing to treatment failure and the emergence of resistant strains. Additionally, negative regulation of drug response can cause adverse drug reactions or reduce drug efficacy in non-target tissues, complicating drug development and clinical management. Understanding this process at the molecular level enables researchers to identify biomarkers of resistance, develop combination therapies, and design next-generation drugs that bypass or overcome negative regulation.
• Mediates resistance to cancer therapies, including chemotherapy and targeted agents.
• Contributes to antibiotic and antiviral treatment failure.
• Influences inter-individual variability in drug efficacy and toxicity.
• Involves drug-metabolizing enzymes and transporters that alter pharmacokinetics.
• Epigenetic regulators such as KDM5A and HDACs can silence drug response genes.
• Nuclear receptors (NR1I2, NR1I3) coordinate transcriptional responses to drugs.
• Provides targets for combination therapies to overcome resistance.
• Can be harnessed to intentionally dampen unwanted drug effects.
• Requires CRISPR functional genomics to identify causal genes.
• Links to personalized medicine and pharmacogenomics.
What Happens During negative regulation of response to drug?
Drug recognition and signal initiation
In simple terms: The cell first senses the drug and starts a response, which negative regulation then tries to shut down.
When a drug enters a cell or binds its target, it initiates a response through receptor activation, enzyme inhibition, or DNA damage. This initial signal is the substrate for negative regulation. For example, kinase inhibitors block oncogenic signaling, but cells can activate compensatory pathways that reduce drug efficacy. The recognition step involves drug-target engagement and downstream signaling events that are subject to negative regulation.
Transcriptional suppression of drug response genes
In simple terms: The cell turns down the genes that would normally help the drug work.
Negative regulation often involves transcriptional repression of genes required for drug sensitivity. Nuclear receptors such as NR1I2 (PXR) and NR1I3 (CAR) can induce drug-metabolizing enzymes (e.g., CYP3A4) that inactivate drugs, thereby reducing response. Conversely, epigenetic silencers such as KDM5A and HDACs can repress pro-apoptotic or pro-senescence genes, blunting drug-induced cell death. These transcriptional changes are central to negative regulation of response to drug.
Drug efflux and metabolism
In simple terms: The cell pumps the drug out or breaks it down, so less drug reaches its target.
ATP-binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein) and ABCG2 actively efflux drugs, reducing intracellular concentrations and diminishing response. Phase I and II metabolizing enzymes, including CYP3A4 and CYP2D6, chemically modify drugs to facilitate excretion, further lowering active drug levels. Upregulation of these systems is a classic mechanism of negative regulation of response to drug.
Activation of survival and anti-apoptotic pathways
In simple terms: The cell turns on survival signals that counteract the drug's killing effect.
Drug-induced stress can activate pro-survival pathways such as PI3K/AKT, MAPK, and NF-kB, which oppose apoptosis and autophagy. For instance, in melanoma, BRAF inhibitor resistance involves reactivation of MAPK signaling through NRAS or MEK mutations. These adaptive responses are negative regulators of drug response and represent therapeutic targets.
Epigenetic remodeling and feedback loops
In simple terms: Long-lasting chemical marks on DNA or histones keep the drug response turned off.
Epigenetic enzymes such as KDM5A (a histone demethylase) and HDACs can establish repressive chromatin states that silence drug response genes. These changes can be heritable, leading to persistent resistance. Feedback loops involving microRNAs and long non-coding RNAs also contribute to negative regulation of drug response. Targeting these epigenetic regulators with CRISPR-based approaches can reverse negative regulation and restore drug sensitivity.
Key Genes Involved in GO:2001024 negative regulation of response to drug
The following genes and proteins are experimentally validated participants in negative regulation of response to drug, based on published literature and QuickGO annotations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP3A4 | Metabolizes drugs, reducing active drug levels | Pharmacokinetic resistance; CRISPR KO alters drug sensitivity |
| CYP2D6 | Metabolizes drugs, affecting drug efficacy | Pharmacogenomics; point mutations alter enzyme activity |
| ABCB1 | Efflux pump that reduces intracellular drug concentration | Multidrug resistance; KO increases drug accumulation |
| ABCG2 | Efflux transporter for various drugs | Cancer and stem cell resistance; KO sensitizes cells |
| NR1I2 (PXR) | Nuclear receptor inducing drug-metabolizing enzymes | Transcriptional regulator of negative response; KO alters CYP expression |
| NR1I3 (CAR) | Nuclear receptor regulating drug metabolism and transport | Similar to PXR; KO affects drug clearance |
| KDM5A | Histone demethylase that represses drug response genes | Epigenetic resistance; KO restores drug sensitivity |
| HDAC1 | Histone deacetylase involved in transcriptional repression | Epigenetic silencing; inhibitors reverse negative regulation |
| HDAC2 | Histone deacetylase contributing to drug resistance | Target for combination therapy |
| TP53 | Tumor suppressor; loss can reduce drug response | Mutational status affects chemotherapy efficacy |
| BCL2 | Anti-apoptotic protein; overexpression reduces drug-induced apoptosis | Target of venetoclax; KO sensitizes to drugs |
| MCL1 | Anti-apoptotic protein; mediates resistance to targeted therapies | CRISPR KO enhances drug sensitivity |
| EGFR | Receptor tyrosine kinase; mutations alter drug response | Point mutations (T790M) cause resistance |
| KRAS | Oncogene; mutations drive resistance to EGFR inhibitors | Knock-in models study resistance mechanisms |
| BRAF | Kinase; mutations and feedback reactivation reduce drug response | CRISPR models for melanoma resistance |
| NRAS | Oncogene; reactivation causes MAPK inhibitor resistance | Overexpression models for resistance |
| MET | Receptor tyrosine kinase; amplification reduces drug response | Knock-in and KO models for resistance |
How Is negative regulation of response to drug Regulated?
Negative regulation of response to drug is itself tightly regulated at multiple levels. Transcriptional control is mediated by nuclear receptors such as NR1I2 (PXR) and NR1I3 (CAR), which sense xenobiotics and induce drug-metabolizing enzymes and transporters. Epigenetic regulation involves histone demethylases (KDM5A) and deacetylases (HDACs) that establish repressive chromatin states. Post-translational modifications, including phosphorylation and ubiquitination, modulate the stability and activity of drug response proteins. Additionally, feedback loops in signaling pathways (e.g., MAPK, PI3K/AKT) can attenuate drug effects. These regulatory layers provide multiple entry points for therapeutic intervention to overcome negative regulation.
negative regulation of response to drug and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB1 | Multidrug resistance in cancer | CRISPR KO in cancer cell lines; drug sensitivity assays |
| KDM5A | Epigenetic resistance to targeted therapy | KO and overexpression models; RNA-seq |
| EGFR | Lung cancer resistance to EGFR inhibitors | Point mutation (T790M) knock-in; drug response assays |
| BCL2 | Leukemia resistance to chemotherapy | Knockout and overexpression; apoptosis assays |
| CYP3A4 | Variable drug metabolism affecting efficacy | CRISPR KO in hepatocytes; pharmacokinetic studies |
Cancer therapy resistance
Negative regulation of response to drug is a major cause of resistance to chemotherapy, targeted therapy, and immunotherapy in cancer. For example, upregulation of ABCB1 or ABCG2 efflux pumps reduces intracellular drug concentrations, while activation of anti-apoptotic proteins (BCL2, MCL1) blunts drug-induced cell death. Epigenetic silencing by KDM5A and HDACs can also confer resistance. Understanding these mechanisms is essential for developing combination strategies to restore drug sensitivity.
Infectious disease treatment failure
In infectious diseases, negative regulation of drug response can lead to antibiotic or antiviral treatment failure. For instance, upregulation of efflux pumps in bacteria or fungi reduces drug accumulation, while host factors may limit drug bioavailability. In HIV treatment, negative regulation of response to drug can contribute to viral persistence and resistance. Addressing these mechanisms is critical for global health.
Neurological and metabolic disorders
Negative regulation of drug response also impacts neurological and metabolic disorders. For example, in epilepsy, upregulation of efflux transporters at the blood-brain barrier reduces antiepileptic drug efficacy. In diabetes, negative regulation of insulin-sensitizing drugs can worsen glycemic control. These examples highlight the broad clinical relevance of GO:2001024.
From negative regulation of response to drug-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KDM5A restore drug sensitivity? | CRISPR knockout in resistant cancer cell lines |
| Does ABCB1 overexpression reduce intracellular drug levels? | CRISPR knock-in of ABCB1 promoter or overexpression |
| Does a specific point mutation in EGFR confer resistance? | Point mutation knock-in (e.g., T790M) |
| Does tagging a drug transporter reveal its localization? | Tagged knock-in (e.g., GFP-ABCB1) |
| Can overexpression of BCL2 block drug-induced apoptosis? | CRISPR overexpression in sensitive cells |
| Which genes negatively regulate response to a novel drug? | Genome-wide CRISPR library screening |
How to Study the negative regulation of response to drug Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on drug response | Identify negative regulators of drug sensitivity |
| RNA-seq | Transcriptional changes after drug treatment | Discover genes suppressed or induced by negative regulation |
| ChIP-seq | Histone modifications and transcription factor binding | Map epigenetic silencing of drug response genes |
| Proteomics | Protein expression and modifications | Quantify drug-metabolizing enzymes and transporters |
| Metabolomics | Drug metabolite levels | Assess metabolic inactivation of drugs |
| High-throughput viability assay | Cell survival after drug treatment | Measure drug sensitivity in edited cells |
| Flow cytometry | Apoptosis and efflux activity | Evaluate BCL2 family and ABCB1 function |
| Bioinformatics pathway analysis | Enriched pathways and networks | Interpret CRISPR screen hits |
CRISPR functional genomics
CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect negative regulation of response to drug. Genome-wide CRISPR screens can identify novel negative regulators by selecting for cells that survive drug treatment. These methods enable causal inference and target validation.
Transcriptomics and epigenomics
RNA-seq and ChIP-seq can reveal transcriptional and epigenetic changes that mediate negative regulation. For example, RNA-seq after drug treatment can identify genes whose expression is suppressed or induced to reduce drug response. ATAC-seq and histone modification ChIP-seq can uncover chromatin remodeling events.
Proteomics and metabolomics
Mass spectrometry-based proteomics can quantify drug-metabolizing enzymes and transporters, while metabolomics can measure drug metabolites. These approaches provide a systems-level view of negative regulation.
High-throughput drug sensitivity assays
Cell viability and apoptosis assays in CRISPR-edited cells can directly measure drug response. Combining these with library screening enables identification of genes whose loss or gain alters drug sensitivity.
How CRISPR Can Be Used to Study GO:2001024 negative regulation of response to drug
Knockout
CRISPR knockout of candidate negative regulators (e.g., KDM5A, ABCB1) can reverse drug resistance and restore sensitivity. Knockout models are essential for loss-of-function studies in GO:2001024.
Point Mutation
Point mutation knock-in (e.g., EGFR T790M) can model clinically relevant resistance mutations that negatively regulate drug response. These models help test next-generation inhibitors.
Knock-in
Knock-in of tagged or reporter constructs (e.g., GFP-ABCB1) enables real-time tracking of drug transporters and their regulation. Knock-in of resistance alleles can also model patient-specific responses.
Overexpression
CRISPR overexpression of anti-apoptotic genes (BCL2, MCL1) or efflux pumps can confer drug resistance and validate negative regulation mechanisms. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports negative regulation of response to drug Research
Researchers studying negative regulation of response to drug-related genes often need to determine whether a candidate gene is causally involved in reducing drug efficacy or whether it is merely a biomarker. Functional validation through precise genome editing is essential to establish causality and to identify actionable targets for overcoming resistance.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of response to drug research.
Frequently Asked Questions About negative regulation of response to drug
What is negative regulation of response to drug (GO:2001024)?
It is a biological process that actively reduces or prevents the cellular, physiological, or behavioral effects of a drug.
What genes are involved in negative regulation of response to drug?
Key genes include CYP3A4, CYP2D6, ABCB1, ABCG2, NR1I2, NR1I3, KDM5A, HDAC1, HDAC2, BCL2, MCL1, EGFR, KRAS, BRAF, NRAS, and MET.
How is negative regulation of response to drug different from drug resistance?
Drug resistance often involves genetic mutations or target alterations, while negative regulation emphasizes active regulatory pathways that suppress drug response.
What diseases are associated with negative regulation of response to drug?
Cancer therapy resistance, infectious disease treatment failure, and neurological disorders such as epilepsy.
What experimental models are used to study GO:2001024?
CRISPR knockout, point mutation, knock-in, overexpression, and genome-wide CRISPR screens.
How can CRISPR screening identify negative regulators of drug response?
By selecting for cells that survive drug treatment after genome-wide knockout, researchers can identify genes whose loss restores drug sensitivity.
What is the role of ABCB1 in negative regulation of response to drug?
ABCB1 is an efflux pump that reduces intracellular drug concentrations, thereby diminishing drug response.
How do epigenetic regulators contribute to negative regulation of response to drug?
Enzymes such as KDM5A and HDACs establish repressive chromatin states that silence drug response genes.
Can negative regulation of response to drug be reversed therapeutically?
Yes, combination therapies targeting efflux pumps, epigenetic regulators, or survival pathways can restore drug sensitivity.
What services does EDITGENE offer for studying GO:2001024?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Negative regulation of response to drug (GO:2001024) is a fundamental biological process that actively suppresses drug efficacy through transcriptional, epigenetic, metabolic, and signaling mechanisms. Its dysregulation contributes to therapeutic resistance in cancer, infectious diseases, and neurological disorders. Understanding the genes and pathways involved is essential for developing strategies to overcome resistance and improve patient outcomes. CRISPR-based functional genomics, combined with high-throughput screening and bioinformatics, offers powerful tools to dissect this process and identify novel therapeutic targets.
References
- 1. Thakur RK et al.. 2025. The promise of menin inhibitors: from approval to triplet regimens.. Hematology Am Soc Hematol Educ Program 2025(1):599-606 PMID: 41347983
- 2. Csete J et al.. 2016. Public health and international drug policy.. Lancet 387(10026):1427-1480 PMID: 27021149
- 3. Liu ITT et al.. 2024. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval.. JAMA 331(17):1471-1479 PMID: 38583175
- 4. Markham A. 2017. Delafloxacin: First Global Approval.. Drugs 77(13):1481-1486 PMID: 28748399
- 5. Azzi A. 2018. Many tocopherols, one vitamin E.. Mol Aspects Med 61:92-103 PMID: 28624327
- 6. Wijenayaka AR et al.. 2016. Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D(3).. J Steroid Biochem Mol Biol 164:369-373 PMID: 26690786
- 7. Cameron F et al.. 2011. Ipilimumab: first global approval.. Drugs 71(8):1093-104 PMID: 21668044
- 8. Roxo U et al.. 2019. Prioritizing the sexual and reproductive health and rights of adolescent girls and young women within HIV treatment and care services in emergency settings: a girl-centered agenda.. Reprod Health 16(Suppl 1):57 PMID: 31138222
